Excipient uses and regulation
Excipients are used in food, beverages, nutritional supplements, personal-care products, and industrial products in addition
to pharmaceutical applications. The food and beverage industry is the primary market for many excipient manufacturers. Facilities
producing food ingredients or food additives that are also sold as excipients are usually dedicated to a single product or
product families produced under food good manufacturing practices (GMPs) (1). These products typically ship from the manufacturer
in finished-goods packages or in bulk to distribution facilities that may hold and package or transfer the product for regional
delivery. This situation presents unique challenges in the excipient supply chain because food GMPs do not contain the appropriate
controls for pharmaceutical excipients. The Joint International Pharmaceutical Excipients Council–Pharmaceutical Quality Group's
(IPEC–PQG) Good Manufacturing Practices for Pharmaceutical Excipient Guide and the IPEC Good Distribution Practices (GDPs)
Guide provide direction on the appropriate controls necessary to ensure pharmaceutical excipient quality.
Food GMPs.
The difference between food processors operating under food GMPs and pharmaceutical makers governed by drug GMPs influences
the quality systems and operational controls their suppliers adopt. Food GMPs focus on sanitation to prevent the introduction
of contaminated or spoiled food. They do not include provisions on quality that ensure the taste, aesthetics, or health benefits
of food. GMPs for finished drug products focus on the controls necessary to ensure the identity, strength, quality, and purity
of the drug product. The rule of thumb of food regulation is that ingredients should not harm the consumer. The emphasis of
drug regulations is that the products also must provide benefit to the health of the patient. Food GMPs do not require specifications
for food ingredients. GMP requirements for incoming-goods inspections in the food industry involve inspection to ascertain
that the ingredients are clean and suitable for processing into food. Raw materials are often purchased under a supplier's
letter of continuing guarantee that assures the ingredient meets food GMP requirements for the absence of pathogens, natural
toxins, pests, or extraneous matter. Food-ingredient suppliers provide a letter of continuing guarantee stating that the products
shipped will not be adulterated under the Food, Drug and Cosmetic Act in place of certificates of analysis (COAs). Manufacturing
personnel release food ingredients for shipment through process-control data monitoring. Their internal audits and controls
focus on sanitation inspections, product protection, and cleaning schedules.
Drug GMPs.
In contrast, drug GMPs require testing of each component for conformity with all written specifications to assure the purity,
strength, and quality of the finished drug product. As a result of their customers' requirements, excipient suppliers have
written release specifications for their products that rely on sampling and testing by a quality unit. Excipient manufacturers
provide COAs for each lot that conveys the results of such testing. Internal audits and controls for excipient manufacturers
ensure that procedures are followed to produce consistent quality excipients.
Distribution practices.
Fungible distribution practices in the food ingredients and industrial chemicals markets, where the same ingredient from
multiple manufacturers and manufacturing locations are comingled in a common storage tank, are commonly used to reduce distribution
costs. Compatible ingredients may be unloaded into storage with no cleaning, relying on the high dilution factor to maintain
product conformance. Samples from these tanks are periodically collected by contract surveyors and tested in local laboratories
against multiple specifications to identify suitable customers. When a food ingredient or additive is sold as an excipient,
the test results on a COA may list each parameter in a United States Pharmacopoeia–National Formulary (USP–NF) monograph with a statement such as "meets USP–NF specifications." This misleading statement, which indicates conformance to the monograph, implies to the pharmaceutical user
that the excipient was manufactured and distributed following appropriate GMPs and GDPs. Conformance to food GMPs is insufficient
to assure that the ingredient quality system adequately conforms to excipient GMPs. As such, product testing simply to determine
compliance with a USP–NF monograph does not mitigate risk and does not indicate that a food ingredient or additive is suitable for use in drug manufacturing.
Documenting excipient quality
It is paramount for the pharmaceutical manufacturer or user to know where and how the excipients were manufactured and to
understand the excipient supply chain thoroughly. The pharmaceutical user is responsible for knowing the excipient pedigree
(2). Qualification of the excipient manufacturer begins with the pharmaceutical user's request for information concerning
regulatory, quality, and site-security details using the Excipient Information Package (EIP) (3). In the past, an excipient
manufacturer would receive questionnaires from each customer, requesting similar information but in different formats and
with differing expectations as to the details. IPEC developed the EIP in a standard format, based upon the material safety
data sheets that are widely used to convey safety information, to facilitate the communication of this information. This standard
document benefits the excipient manufacturer because it provides the essential information that all pharmaceutical users need
while assuring the pharmaceutical customer receives detailed information and is notified of changes to the content of the
EIP (4).
Many times excipients are not sold directly to the user, but instead go from the excipient manufacturer to a distributor that
sells them to the pharmaceutical user. Distributors should maintain the manufacturer's EIP on file to facilitate the delivery
of the document from the excipient manufacturer to the pharmaceutical user.
|